following an abbreviated submission:
estradiol / micronised progesterone (Bijuve®) is accepted for use within NHSScotland.
Indication under review: continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses. The experience in treating women older than 65 years is limited.
Estradiol / micronised progesterone (Bijuve®) offers an additional treatment choice of continuous combined hormone replacement therapy.
Download detailed advice729KB (PDF)
Medicine details
- Medicine name:
- estradiol / micronised progesterone (Bijuve)
- SMC ID:
- SMC2502
- Indication:
Continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses. The experience in treating women older than 65 years is limited.
- Pharmaceutical company
- Theramex UK LTD
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 September 2022